Dividends CAGR: N/A

Dividends CAGR uses the stored dividend-per-share history.

Over the past 12 months, Dividends CAGR is N/A. Dividends CAGR shows the annualized change in the company's dividend payments per share over the selected period.

dividends overview dividends per share dividend yield payout ratio fcf payout ratio

CYTK Dividends CAGR Chart

No data available

Dividends CAGR History

No historical data available

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

South San Francisco, CA

673 employees

www.cytokinetics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert I. Blum

View full financials